1. Introduction {#sec1}
===============

Psoriasis is a common chronic inflammatory skin disease whose main pathological manifestations were inflammation, hyperproliferation of the epidermis, altered maturation of the epidermis, and vascular alterations \[[@B1]\]. The prevalence of this disease ranges from 0.51% to 11.43% in different countries \[[@B2]\]. Itching is the main symptom in different degrees; it has a great influence on the quality of life of patients and easily leads to social and psychological disorder such as inferiority, depression, and anxiety \[[@B3]\]. The pathogenesis of psoriasis is always believed to be a combination of immunologic disarrangement, psoriasis-associated susceptibility loci, psoriasis autoantigens, and multiple environmental factors; however, current research shows that psoriasis is a T-cell mediated disease primarily driven by pathogenic T-cells \[[@B4]\]. In an animal experiment, it is observed in the imiquimod-induced psoriasis-like mice that the epidermal expression of IL-23, IL-17A, and IL-17F is increased, whereas disease development was almost completely blocked in mice deficient for IL-23 or the IL-17 receptor \[[@B5]\]. Moreover, some of these studies did explore that IL-23 which is secreted by dermal dendritic cells (DDC) can induce the activation of Th17 lymphocytes and lead to the release of proinflammatory cytokines such as IL-17A, IL-17F, IL-22, IL-26, TNF-*α*, and IFN-*γ*. The complex interactions of these cytokines ultimately lead to epidermal hyperplasia, recruitment of neutrophils, and angiogenesis \[[@B6]\]. Recently, several studies have investigated that IL-12 and IL-23 share a common subunit (p40). Transgenic mice that overexpress IL-12 p40 develop inflammatory skin lesions \[[@B7]\]. Therefore, based on the theory of IL-12 and IL-23/IL-17 signal transduction pathway, blocking the important loci of signal axis has become a potential therapy to destroy the inflammatory cycle of psoriasis.

Fortunately, IL12/23, IL-17, and newer IL-23p19 antagonists have been produced and applied in clinics which shows a translational revolution in the treatment and management of psoriasis. Several studies have summarized the efficacy and safety data of IL-17 and IL-23 agents, but the results are inadequate \[[@B8], [@B9]\]. In addition, other NMA were made at the class level of medications, but not at the dosage level \[[@B10]\]. Therefore, we perform a systematic review with the NMA of all randomized trials to compare short-term treatment efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab at the dosage level for moderate to severe plaque psoriasis.

2. Materials and Methods {#sec2}
========================

2.1. Study Identification {#sec2.1}
-------------------------

Our NMA was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement \[[@B11]\].

A computer-based literature search was performed to identify the available relevant studies published before August 1, 2018, in PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL), and clinical trials registered at ClinicalTrials.gov were searched for details of any relevant clinical trials in progress. We used the terms "ustekinumab or stelara or CNTO 1275 or guselkumab or tildrakizumab or SCH 900222 or MK-3222 or risankizumab or BI 655066 or secukinumab or cosentyx or AIN 457 or brodalumab or siliq or AMG-827 or lumicef or ixekizumab or taltz or LY2439821" and "psoriasis." Vocabulary and syntax were adapted to be appropriate for each database. Standardized filters were applied for study designs, including the Cochrane highly sensitive search strategy for randomized controlled trials. Language was restricted to English. Comments, editorials, and letters were removed. The search strategy was shown in Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}.

2.2. Study Selection {#sec2.2}
--------------------

We determined the inclusion and exclusion criteria before the search. The included studies should fulfill the following criteria: study design was limited to randomized, double-blind, placebo-controlled trials; adult patients (age \> 18 years) are of either sex with a diagnosis of moderate to severe plaque psoriasis; the study should provide at least one efficacy outcome for short-term treatment: (1) 75% or greater reduction from baseline in the psoriasis area and severity index (PASI 75), (2) 100% reduction from baseline in the psoriasis area and severity index (PASI 100), (3) static physician\'s global assessment score of 0 or 1 (sPGA 0/1), (4) modified investigator\'s global assessment score of 0 or 1 (IGA 0/1), and (5) physician\'s global assessment score of 0 or 1 (PGA 0/1); the study should provide at least one safety outcome for short-term treatment: (1) one or more adverse events (AEs), (2) one or more serious adverse events (sAEs), and (3) discontinuations due to AEs. The exclusion criteria were as follows: the patients with psoriasis were under 18 years of age.

2.3. Data Abstraction and Quality Assessment {#sec2.3}
--------------------------------------------

Two independent investigators abstracted the data using a standard data extraction form, and any disagreement will be resolved by a third author. The following information will be extracted from each included article: author, year of publication, journal, drug, time to evaluate, primary endpoint, details of the interventions, sample size, male proportion, age, duration of psoriasis, involved body surface area (%), and baseline psoriasis area and severity index (PASI) score.

Two authors independently assessed the quality of each included study in accordance with the Cochrane handbook of systematic reviews of interventions 5.1.0 (updated March 2011), which covers the following: (1) random sequence generation (selection bias), (2) allocation concealment (selection bias), (3) blinding of participants and treatment providers (performance bias), (4) blinding of outcome assessors (detection bias), (5) incomplete outcome data (attrition bias), (6) selective reporting (reporting bias), and (7) other biases. Disagreements between the review authors over the risk of bias in particular studies were resolved by a third review author.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Clinical data were synthesized through narrative review with tabulation of the results of the included studies. Where sufficient clinically and statistically homogenous data were available, data were pooled using appropriate meta-analytic techniques.

Stata V.15.0 (StataCorp, College Station, TX, USA) \[[@B12]\] in a frequentist framework was used to perform network meta-analysis (NMA) which can make direct and indirect evidences comparable. No matter what interventions the subjects actually received, they were grouped according to the initial random statistics. If only percentages were reported, the results were estimated according to the nearest total number of events. When there was a missing value, we contacted the authors to provide the missing outcome data. Otherwise, the treatment was assumed to fail. We used the netleague command to report the RRs with corresponding 95% confidence intervals (CIs) between two comparisons, and the results were presented in a tabular form. We also ranked the efficacy and safety for each drug. The surface under the cumulative ranking curve (SUCRA) ranges from 0% to 100% were determined as an estimation of the ranking probability for each medication. For efficacy indicators, the larger the area under the curve, the better the effect. For safety indicators, the larger the area under the curve, the better the tolerance. The inconsistency and statistical disagreement between direct and indirect evidences were performed by the loop-specific method in each loop locally. And the relative odds ratio (ROR) with 95% CIs could be used to calculate clinical authenticity of NMA. If the ROR is close to 1 or the 95% CIs include 0, the similar effect estimations for direct evidence and indirect evidence are consistent \[[@B13]\]. Additional sensitivity analyses were performed by excluding the trials at the high risk of bias to evaluate the robustness of our findings. Publication bias was estimated by comparison-adjusted funnel plots.

3. Results {#sec3}
==========

3.1. Search Strategy {#sec3.1}
--------------------

In total, 6801 publications matching the search criteria were identified. After removing the duplicate publications, titles and abstracts of the remaining 4945 publications were screened. 4899 publications were irrelevant records, and 46 publications were ultimately determined with eligibility. Based on the inclusion and exclusion criteria, 23 articles including 28 randomized, double-blind, placebo-controlled clinical trials were assessed in this meta-analysis \[[@B14]--[@B36]\]: 5 trials of brodalumab, 5 trials of secukinumab, 3 trials of ixekizumab, 6 trials of ustekinumab, 4 trials of guselkumab, 3 trials of tildrakizumab, and 2 trials of risankizumab. The flowchart for the selection of eligible studies is shown in [Figure 1](#fig1){ref-type="fig"}.

The characteristics of the included studies are shown in [Table 1](#tab1){ref-type="table"}. 19840 patients with psoriasis in 28 trials were included in this meta-analysis. Except 7 phase II trials, the rest were all phase III trials. 21 trials evaluated the short-term outcomes at weeks 12 and 7 trials at weeks 16. We collected the major clinical responses and safety indicators such as PASI 75, PASI 100, sPGA 0/1, IGA 0/1, PGA 0/1, AEs, SAEs, and discontinuations due to AEs in [Table 2](#tab2){ref-type="table"}.

3.2. Risk of Bias {#sec3.2}
-----------------

We summarized the risk of bias in [Figure 2](#fig2){ref-type="fig"}.

### 3.2.1. Random Sequence Generation {#sec3.2.1}

Among the 28 studies, the patients in 22 studies \[[@B14]--[@B17], [@B19], [@B21]--[@B23], [@B25]--[@B27], [@B31]--[@B36]\] were randomized via computer-programmed random sequence or random number generator and were thus evaluated having the low risk of bias. Five studies \[[@B18], [@B20], [@B28]--[@B30]\] did not mention the method or detail of random sequence generation and were evaluated having an unclear risk of bias. The patients in 1 study \[[@B24]\] were not administered in a blinded, placebo-controlled manner evaluated as the high risk of bias.

### 3.2.2. Allocation Concealment {#sec3.2.2}

11 studies \[[@B14], [@B16], [@B17], [@B33]--[@B36]\] used a validated system that automated the random assignment of medication numbers or sequentially numbered containers and were given a low risk of bias; 16 studies \[[@B18]--[@B32]\] did not describe any method to blind the random sequence and were evaluated having an unclear risk of bias. One study \[[@B15]\] divided the patients in turns and was regarded having a high risk of bias.

### 3.2.3. Blinding of Participants and Treatment Providers {#sec3.2.3}

One study \[[@B29]\] did not specify how to perform blinding and was regarded having an unclear risk of bias; the rest of the studies were all double or triple blinded with a low risk of bias.

### 3.2.4. Blinding of Outcome Assessors {#sec3.2.4}

21 studies \[[@B14]--[@B17], [@B23], [@B24], [@B29]--[@B36]\] specified that the evaluators are blinded and were given a low risk of bias. Seven studies \[[@B18]--[@B22], [@B25], [@B28]\] only blinded the participants and personnel and were given a high risk of bias.

### 3.2.5. Incomplete Outcome Data {#sec3.2.5}

Four studies \[[@B15], [@B16], [@B23]\] did not report the reasons for missing data and were given a high risk of bias. The rest of the studies which performed the statistical analysis of data based on intention to treat were regarded having a low risk of bias.

### 3.2.6. Selective Reporting {#sec3.2.6}

One study \[[@B23]\] did not preset the major outcome indicators, so we considered the quality of this study as a high risk of bias; the rest of the studies registered the protocol and reported the main outcomes and were evaluated having a low risk of bias.

### 3.2.7. Other Biases {#sec3.2.7}

The evidence to judge the other biases was not enough, so we regarded the other biases of all the studies as an unclear risk of bias.

3.3. Network Meta-Analysis {#sec3.3}
--------------------------

### 3.3.1. Network Plot {#sec3.3.1}

We built 6 networks involving 6 major outcomes. And each network plot involved 13 different dosages of 7 different biologics. The summarized network plots of the comparisons are provided in [Figure 3](#fig3){ref-type="fig"}. The number of both studies and subjects on ustekinumab 45 mg was the most frequent among all the interventions.

*(1) PASI 75*. With regard to PASI 75, all the interventions performed better than placebo, and the effect size was the strongest for ixekizumab 80 mg every 2 weeks (RR = 18.64, 95% CI 13.46, 25.80) and secukinumab 300 mg (RR = 18.17, 95% CI 12.79, 25.81). In the mixed comparisons, ixekizumab 80 mg every 2 weeks was superior compared with ixekizumab 80 mg every 4 weeks (RR = 1.09, 95% CI 1.04, 1.14), ustekinumab 90 mg (RR = 1.53, 95% CI 1.05, 2.22), ustekinumab 45 mg (RR = 1.69, 95% CI 1.17, 2.45), guselkumab 100 mg (RR = 1.72, 95% CI 1.09, 2.72), guselkumab 50 mg (RR = 1.63, 95% CI 1.02, 2.61), and brodalumab 140 mg (RR = 1.74, 95% CI 1.20, 2.53). Secukinumab 300 mg was more effective than secukinumab 150 mg (RR = 1.15, 95% CI 1.07, 1.23), ustekinumab 45 mg (RR = 1.65, 95% CI 1.11, 2.45), guselkumab 100 mg (RR = 1.68, 95% CI 1.04, 2.70), and brodalumab 140 mg (RR = 1.70, 95% CI 1.14, 2.52). Risankizumab 150 mg performed better than ustekinumab 45 mg (RR = 1.24, 95% CI 1.12, 1.37) and brodalumab 140 mg (RR = 1.27, 95% CI 1.12, 1.44). There was no significant difference in the efficacy of ixekizumab 80 mg every 2 weeks and secukinumab 300 mg (RR = 0.97, 95% CI 0.60, 1.57). Network meta-analysis results for PASI 75 are presented in [Figure 4](#fig4){ref-type="fig"}. The corresponding forest plot is detailed in Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}.

*(2) PASI 100*. With regard to PASI 100, all the interventions were significantly superior than placebo. The effect size was the strongest for ixekizumab 80 mg every 2 weeks (RR = 81.67, 95% CI 27.65, 241.26) and brodalumab 210 mg (RR = 75.50, 95% CI 38.76, 147.04). In the mixed comparisons, brodalumab 210 mg was more effective than brodalumab 140 mg (RR = 1.61, 95% CI 1.27, 2.04), ustekinumab 90 mg (RR = 2.98, 95% CI 1.78, 4.98), ustekinumab 45 mg (RR = 3.06, 95% CI 2.10, 4.46), tildrakizumab 200 mg (RR = 5.42, 95% CI 1.26, 23.31), and tildrakizumab 100 mg (RR = 5.30, 95% CI 1.23, 22.80). Brodalumab 140 mg performed better than ustekinumab 90 mg (RR = 1.85, 95% CI 1.11, 3.10) and ustekinumab 45 mg (RR = 1.90, 95% CI 1.31, 2.78). Ixekizumab 80 mg every 2 weeks was found to be more efficacious than tildrakizumab 200 mg (RR = 5.87, 95% CI 1.08, 31.81) and tildrakizumab 100 mg (RR = 5.74, 95% CI 1.06, 31.11). Network meta-analysis results for PASI 100 are presented in [Figure 5](#fig5){ref-type="fig"}. The corresponding forest plot is detailed in Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}.

*(3) sPGA 0/1 or IGA 0/1 or PGA 0/1*. With regard to sPGA 0/1 or IGA 0/1 or PGA 0/1, the biologics involved were statistically significantly superior to placebo. The effect size was the strongest for secukinumab 300 mg (RR = 26.51, 95% CI 16.51, 42.54) and secukinumab 150 mg (RR = 21.05, 95% CI 13.10, 33.85). In the mixed comparisons, secukinumab 300 mg was more effective than secukinumab 150 mg (RR = 1.26, 95% CI 1.15, 1.38), ustekinumab 90 mg (RR = 2.27, 95% CI 1.36, 3.79), tildrakizumab 200 mg (RR = 2.47, 95% CI 1.30, 4.72), risankizumab 150 mg (RR = 1.82, 95% CI 1.09, 3.06), guselkumab 100 mg (RR = 2.43, 95% CI 1.39, 4.25), and brodalumab 210 mg (RR = 1.83, 95% CI 1.10, 3.05). Brodalumab 210 mg performed better than ustekinumab 90 mg (RR = 1.24, 95% CI 1.13, 1.37) and ustekinumab 45 mg (RR = 1.35, 95% CI 1.26, 1.45). Network meta-analysis results for sPGA 0/1 or IGA 0/1 or PGA 0/1 responses are presented in [Figure 6](#fig6){ref-type="fig"}. The corresponding forest plot is detailed in Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}.

*(4) AEs*. In terms of having a risk of AEs, the rate was higher in secukinumab 300 mg, secukinumab 150 mg, ustekinumab 45 mg, brodalumab 210 mg and brodalumab 140 mg, ixekizumab 80 mg every 4 weeks, and ixekizumab 80 mg every 2 weeks compared to placebo. The effect size was the strongest for ixekizumab 80 mg every 4 weeks (RR = 1.26, 95% CI 1.15, 1.37) and ixekizumab 80 mg every 2 weeks (RR = 1.24, 95% CI 1.14, 1.36). In the mixed comparisons, secukinumab 150 mg was more likely to result in AEs than ustekinumab 90 mg (RR = 1.19, 95% CI 1.05, 1.35), tildrakizumab 200 mg (RR = 1.29, 95% CI 1.11, 1.49), and tildrakizumab 100 mg (RR = 1.28, 95% CI 1.10, 1.48). There was no significant difference between ixekizumab 80 mg every 2 weeks and ixekizumab 80 mg every 4 weeks (RR = 1.01, 95% CI 0.94, 1.08). Network meta-analysis results for AEs are presented in [Figure 7](#fig7){ref-type="fig"}. The corresponding forest plot is detailed in Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}.

*(5) sAEs*. In terms of having a risk of sAEs, no significant difference was observed between these biologics and placebo. Besides, in the mixed comparisons, the rate was higher in ixekizumab 80 mg every 4 weeks compared to risankizumab 150 mg (RR = 2.97, 95% CI 1.01, 8.77). Network meta-analysis results for sAEs are presented in [Figure 8](#fig8){ref-type="fig"}. The corresponding forest plot is detailed in Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}.

*(6) Discontinuations due to AEs*. In terms of having a risk of discontinuations due to AEs, ustekinumab 45 mg and risankizumab 150 mg present a relatively lower risk than placebo; RR were 0.47 (95% CI 0.24, 0.93) and 0.22 (95% CI 0.06, 0.79), respectively. In the mixed comparisons, ixekizumab 80 mg every 4 weeks was more likely to result in discontinuations due to AEs than ustekinumab 45 mg (RR = 4.07, 95% CI 1.45, 11.44), risankizumab 150 mg (RR = 8.72, 95% CI 1.95, 39.08), and guselkumab 50 mg (RR = 7.04, 95% CI 1.06, 46.91). Network meta-analysis results for discontinuations are presented in [Figure 9](#fig9){ref-type="fig"}. The corresponding forest plot is detailed in Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}.

3.4. Ranking of Treatments by Efficacy {#sec3.4}
--------------------------------------

The summarized efficacy and safety ranking of the 13 interventions according to their surface under the cumulative ranking curves (SUCRA) are shown in [Table 3](#tab3){ref-type="table"}; SUCRA for each treatment included in the network are presented in [Figure 10](#fig10){ref-type="fig"}. The ranking for short-term achievements of PASI 75 from high to low was as follows: ixekizumab 80 mg every 2 weeks (SUCRA: 93.0%), secukinumab 300 mg (SUCRA: 89.9%), ixekizumab 80 mg every 4 weeks (SUCRA: 81.5%), secukinumab 150 mg (SUCRA: 73.5%), brodalumab 210 mg (SUCRA: 62.5%), risankizumab 150 mg (SUCRA: 62.3%), ustekinumab 90 mg (SUCRA: 44.5%), tildrakizumab 200 mg (SUCRA: 42.2%), guselkumab 50 mg (SUCRA: 38.7%), tildrakizumab 100 mg (SUCRA: 33.2%), guselkumab 100 mg (SUCRA: 28.5%), ustekinumab 45 mg (SUCRA: 27.4%), and brodalumab 140 mg (SUCRA: 22.8%). The ranking for short-term achievements of PASI 100 from high to low was as follows: brodalumab 210 mg (SUCRA: 85.0%), ixekizumab 80 mg every 2 weeks (SUCRA: 83.3%), ixekizumab 80 mg every 4 weeks (SUCRA: 76.8%), risankizumab 150 mg (SUCRA: 71.3%), brodalumab 140 mg (SUCRA: 63.4%), secukinumab 300 mg (SUCRA: 62.4%), guselkumab 100 mg (SUCRA: 61.4%), guselkumab 50 mg (SUCRA: 55.9%), ustekinumab 90 mg (SUCRA: 34.5%), ustekinumab 45 mg (SUCRA: 33.1%), secukinumab 150 mg (SUCRA: 31.0%), tildrakizumab 100 mg (SUCRA: 21.9%), and tildrakizumab 200 mg (SUCRA: 20.0%). The ranking for short-term achievements of sPGA 0/1 or IGA 0/1 or PGA 0/1 from high to low was as follows: secukinumab 300 mg (SUCRA: 98.1%), ixekizumab 80 mg every 2 weeks (SUCRA: 86.5%), secukinumab 150 mg (SUCRA: 85.7%), ixekizumab 80 mg every 4 weeks (SUCRA: 75.7%), risankizumab 150 mg (SUCRA: 66.7%), brodalumab 210 mg (SUCRA: 65.4%), ustekinumab 90 mg (SUCRA: 42.8%), tildrakizumab 200 mg (SUCRA: 34.7%), guselkumab 50 mg (SUCRA: 33.4%), brodalumab 140 mg (SUCRA: 32.0%), guselkumab 100 mg (SUCRA: 31.4%), ustekinumab 45 mg (SUCRA: 25.4%), and tildrakizumab 100 mg (SUCRA: 22.3%).

3.5. Ranking of Treatments by Safety {#sec3.5}
------------------------------------

According to the SUCRA, the ranking for the short-term risk of adverse events from high to low was as follows: ixekizumab 80 mg every 4 weeks (SUCRA: 4.5%), ixekizumab 80 mg every 2 weeks (SUCRA: 7.5%), secukinumab 150 mg (SUCRA: 22.7%), brodalumab 210 mg (SUCRA: 23.7%), secukinumab 300 mg (SUCRA: 33.9%), brodalumab 140 mg (SUCRA: 38.1%), ustekinumab 45 mg (SUCRA: 41.0%), guselkumab 100 mg (SUCRA: 63.4%), risankizumab 150 mg (SUCRA: 67.6%), ustekinumab 90 mg (SUCRA: 75.2%), guselkumab 50 mg (SUCRA: 76.2%), tildrakizumab 100 mg (SUCRA: 88.8%), and tildrakizumab 200 mg (SUCRA: 90.2%). The ranking for the short-term risk of serious adverse events from high to low was as follows: guselkumab 50 mg (SUCRA: 25.9%), ixekizumab 80 mg every 4 weeks (SUCRA: 27.5%), secukinumab 150 mg (SUCRA: 30.7%), secukinumab 300 mg (SUCRA: 35.6%), brodalumab 140 mg (SUCRA: 38.4%), tildrakizumab 200 mg (SUCRA: 41.1%), guselkumab 100 mg (SUCRA: 49.4%), ixekizumab 80 mg every 2 weeks (SUCRA: 50.8%), ustekinumab 90 mg (SUCRA: 52.5%), ustekinumab 45 mg (SUCRA: 61.1%), brodalumab 210 mg (SUCRA: 63.9%), tildrakizumab 100 mg (SUCRA: 70.8%), and risankizumab 150 mg (SUCRA: 92.8%). The ranking for the short-term risk of discontinuations due to adverse events from high to low was as follows: ixekizumab 80 mg every 4 weeks (SUCRA: 10.7%), ixekizumab 80 mg every 2 weeks (SUCRA: 14.8%), guselkumab 100 mg (SUCRA: 32.1%), tildrakizumab 200 mg (SUCRA: 35.4%), secukinumab 300 mg (SUCRA: 42.2%), secukinumab 150 mg(SUCRA: 43.5%), ustekinumab 90 mg (SUCRA: 49.7%), brodalumab 140 mg (SUCRA: 54.2%), tildrakizumab 100 mg (SUCRA: 58.6%), brodalumab 210 mg (SUCRA: 63.0%), ustekinumab 45 mg (SUCRA: 79.0%), guselkumab 50 mg (SUCRA: 84.6%), and risankizumab 150 mg (SUCRA: 92.6%).

3.6. Inconsistency {#sec3.6}
------------------

Inconsistency refers to the difference between direct and indirect evidences, which will affect the authenticity of network meta-analysis. We used the relative odds ratio (ROR) with 95% CIs to calculate the absolute difference between direct and indirect evidences. If the ROR is close to 1, or the 95% CIs include 0, the effect estimations for direct and indirect evidences are consistent. The results of PASI 100, sPGA 0/1 or IGA 0/1 or PGA 0/1, AEs, sAEs, and discontinuations due to AEs showed no significant inconsistencies in all closed loops which revealed the consistency model\'s conclusions were robust. For PASI 75, there was statistical loop inconsistency in the loop containing placebo, ustekinumab 45 mg, and ustekinumab 90 mg in the combined results of direct and indirect evidences (ROR = 2.114, 95% CI 1.36, 3.28). Inconsistency plots in closed loops for all the outcomes are shown in [Figure 11](#fig11){ref-type="fig"}.

3.7. Sensitivity Analysis {#sec3.7}
-------------------------

Considered PASI 100 and sPGA 0/1 or IGA 0/1 or PGA 0/1 responses are more relevant to the psoriasis patient, we performed sensitivity analyses with these outcomes by excluding the trials at a high risk of bias to evaluate the robustness of our findings. Results were consistent with the main analysis for the efficacy outcomes. And the forest plots are detailed in Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}-[](#supplementary-material-1){ref-type="supplementary-material"}.

### 3.7.1. Publication Bias {#sec3.7.1}

Comparison-adjusted funnel plots of all the outcomes in network meta-analysis are shown in [Figure 12](#fig12){ref-type="fig"}. We found no evidence of publication bias in the result of "AEs" and "discontinuations due to AEs." However, the results of other outcomes were not absolutely symmetrical which suggested publication bias may exist.

4. Discussion {#sec4}
=============

In recent years, biological agents have been widely used in dermatology, especially in patients with chronic psoriasis. Many clinical trials have shown that biological agents can quickly control the illness and improve life quality. Meanwhile, the safety of biological agents has also attracted the attention of dermatologists. Therefore, we summarized and evaluated the short-term therapeutic efficacy and safety of IL-17, IL-12/23, and IL-23 biological agents for the treatment of moderate to severe plaque psoriasis. We extracted direct and indirect evidences from 28 trials with 19840 patients into this meta-analysis. Among these studies, except for 7 phase II trials \[[@B17], [@B18], [@B20], [@B24], [@B29], [@B30], [@B32]\], the others were all phase III trials. All of them were placebo-controlled, and a parallel assignment study contained at least two different doses with the exception of 2 trials that included only one dose with no active controller \[[@B19], [@B23]\]. In addition, the primary endpoints were all assessed at 12 or 16 weeks.

In order to make the efficacy and safety data of these medications comparable, we performed a NMA to compare the indirect evidences in this quantitative meta-analysis. We found that all biologics involved were more efficacious than placebo in achieving PASI 75, PASI 100, and sPGA 0/1 or IGA 0/1 or PGA 0/1 responses. IL-17 inhibitors achieved outstanding performance in the treatment effect at 12 weeks compared with IL-12/23 and IL-23 inhibitors. For PASI 75, ixekizumab 80 mg every 2 weeks ranked first, followed by secukinumab 300 mg, ixekizumab 80 mg every 4 weeks, secukinumab 150 mg and brodalumab 210 mg. For PASI 100, brodalumab 210 mg ranked first, followed by ixekizumab 80 mg every 2 weeks and ixekizumab 80 mg every 4 weeks. Studies showed that about 42% of patients treated with brodalumab 210 mg reached PASI 100 at 12 weeks, while only 0.4% of patients treated with placebo reached PASI 100 at 12 weeks \[[@B28]\]. For sPGA 0/1 or IGA 0/1 or PGA 0/1 responses, secukinumab 300 mg ranked first, followed by ixekizumab 80 mg every 2 weeks, secukinumab 150 mg, ixekizumab 80 mg every 4 weeks and risankizumab 150 mg. In addition, three trials of ixekizumab observed the improvement of the Dermatological Life Quality Index (DLQI) in patients with moderate to severe plaque psoriasis. Data showed that DLQI improved rapidly in the second week after the treatment with ixekizumab, and more than 60% of patients received DLQI (0/1) at 12 weeks without psoriasis symptoms \[[@B35], [@B36]\]. It was noteworthy that in the use of brodalumab, secukinumab, and ixekizumab, high-dose drugs or high-frequency drugs were more effective than low-dose drugs or low-frequency drugs. Risankizumab is a new type of IL-23 inhibitor, whose short-term efficacy was better than other IL-23 or IL-12/23 inhibitors. The results for short-term safety assessment showed that the risk of adverse events in brodalumab 210 mg, brodalumab 140 mg, secukinumab 300 mg, secukinumab 150 mg, ixekizumab 80 mg every 4 weeks, ixekizumab 80 mg every 2 weeks, and ustekinumab 45 mg was higher than that in the placebo group at 12 or 16 weeks. It showed that IL-17 inhibitors were less tolerant than other biological agents. It was also worth noting that the tolerance of ixekizumab 80 mg every 4 weeks was often worse than that of ixekizumab 80 mg every 2 weeks and was associated with greater likelihood of causing sAEs and discontinuations. There was no significant difference in the short-term adverse event risk between other biological agents and placebo. According to the clinical trials, the most relevant adverse events were nasopharyngitis, upper respiratory tract inflammation, and injection site reaction. Guselkumab is a kind of biological therapy that selectively blocked IL-23 \[[@B37]\]. In the 100 mg treatment group, the short-term risk of adverse events was lower than that of other biological agents; however, the risk of discontinuations was high, which may limit its clinical use. In the 50 mg treatment group, the short-term risk of adverse events and discontinuations was low, but the risk of serious adverse events ranked first, so a long-term follow-up of guselkumab is necessary to examine its treatment tolerability. The present meta-analysis included a kind of IL-12/23 inhibitor named ustekinumab which blocked not only the IL-12 but also the IL-23 \[[@B38]\]. Though the risk of adverse events was higher in ustekinumab 45 mg than that in placebo, the risk of discontinuations in the ustekinumab 45 mg and risankizumab 150 mg groups was lower than that in placebo. In ustekinumab 45 mg, only 6 out of 1013 patients abandoned treatment because of adverse events, while 23 out of 983 patients in the placebo group. In the risankizumab 150 mg, 3 out of 598 patients abandoned treatment because of adverse events, while 5 out of 200 patients in the placebo group \[[@B18]--[@B23], [@B34]\]. Not only that, risankizumab 150 mg had a lower risk of adverse events and serious adverse events compared with other IL-23 inhibitors, showing relatively high clinical efficacy and low treatment risk.

Our findings indicated efficacy and safety differences among the biologic agents used in moderate to severe plaque psoriasis which could provide valuable references to clinicians. The strengths in, firstly, our research included the latest biological agents for psoriasis treatment. Tildrakizumab had been licensed for treating psoriasis patients by the FDA in March 2018, and risankizumab had been approved by the FDA in Apirl 2019. Secondly, our study included a large number of patients and high quality of RCTs availabled at present. We compared different drugs at the dose level which not only increased the credibility of our research but also provided more information to the clinicians. Thirdly, previous studies took more attention on PASI 75 and PASI 90. However, PASI 100 is more relevant to the patients. In order to better reflect the efficacy of these drugs, we included PASI 100 in the evaluation of the primary outcomes.

Some potential limitations could affect the interpretation of our findings. Firstly, a placebo-controlled study was conducted during the induction period; however, the study design of the maintenance stage varied and usually the lack of a placebo-control group which increased the difficulty to extract and analyze all the data. So we evaluated the primary endpoints at the end of the induction period (12-16 weeks), whether the biologic agents can ultimately improve the quality of life of psoriasis patients is still unclear and requires more researches to continue. Secondly, some studies lack details of randomization sequence generation, allocation concealment, and blinding, which could reduce the reliability of our results. Therefore, to ensure the authenticity of the results, we made a sensitivity analysis with these outcomes by excluding the trials at a high risk of bias to evaluate the robustness of our findings. Results were consistent with the main analysis for the efficacy outcomes which could strengthen our analysis. Thirdly, few head to head trials available in our NMA, and most of the analyses were based on the indirect comparisons which may limit the consistency evaluation. Fourthly, there were more Americans and Canadians involved in the trials than Asians, so the results of this analysis may not be generalized to all the people in the world. Finally, the analysis has not considered the different medical histories of the patients, which may affect the findings and results.

5. Conclusions {#sec5}
==============

IL-17, IL-12/23, and IL-23 inhibitors had high efficacy in the achievement of PASI 75, PASI 100, and sPGA 0/1 or IGA 0/1 or PGA 0/1 in moderate to severe plaque psoriasis after 12 or 16 weeks of treatment. IL-17 inhibitors brodalumab, secukinumab, and ixekizumab showed superior efficacy in current clinical trials. However, the clinical safety of IL-17 inhibitors was weaker than that of IL-12/23 and IL-23 inhibitors. Ustekinumab was the only IL-12/23 inhibitor included in this study which performed mediocre in both efficacy and tolerance. The IL-23 inhibitor risankizumab is an excellent performer with high efficacy and low risk. The clinical tolerance of other biological agents needs to be further observed. These results may provide a new choice for a clinical treatment of plaque psoriasis. However, further clinical head to head trials are needed to confirm the long-term efficacy and safety of action of the interventions. And treatment decisions should also be based on the associated cost-effectiveness.
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###### 

Click here for additional data file.

![Flowchart for the selection of eligible studies.](JIR2019-2546161.001){#fig1}

![Risk of bias summary.](JIR2019-2546161.002){#fig2}

![Network plots for all the evaluated outcomes at 12 or 16 weeks. The sizes of the nodes are weighted by the sample of interventions, and the widths of lines are weighed by the number of the studies involved. PASI 75: the percentages of patients with a 75% improvement from baseline in the PASI score; PASI 100: the percentages of patients with a 100% improvement from baseline in the PASI score; sPGA 0/1: static physician\'s global assessment score of 0 or 1; IGA 0/1: a response of 0 or 1 on the modified investigator\'s global assessment; PGA 0/1: physician\'s global assessment score of 0 or 1; AEs: adverse events; sAEs: serious adverse events. Alphabetic reference: A, brodalumab 140 mg; B, brodalumab 210 mg; C, guselkumab 100 mg; D, guselkumab 50 mg; E, ixekizumab 80 mg Q2W; F, ixekizumab 80 mg Q4W; G, placebo; H, risankizumab 150 mg; I, secukinumab 150 mg; J, secukinumab 300 mg; K, tildrakizumab 100 mg; L, tildrakizumab 200 mg; M, ustekinumab 45 mg; and N, ustekinumab 90 mg.](JIR2019-2546161.003){#fig3}

![Relative risk with 95% CIs of all interventions from network meta-analysis for PASI 75. Different interventions in the middle block divide the graph into upper and lower triangles; for the lower triangle, the efficacy estimate is the ratio of the column defining treatment to the row defining treatment. In case that the confidence interval does not include 1, if RR \> 1, it favors the column defining treatment. In contrast, if RR \< 1, it favors the row defining treatment. The upper triangle is symmetrical to the lower triangle. The efficacy estimate is the ratio of the row defining treatment to the column defining treatment. The results are mutually reciprocal. Statistically significant results have been applied with italic formatting.](JIR2019-2546161.004){#fig4}

![Relative risk with 95% CIs of all interventions from network meta-analysis for PASI 100. Different interventions in the middle block divide the graph into upper and lower triangles; for the lower triangle, the efficacy estimate is the ratio of the column defining treatment to the row defining treatment. In case that the confidence interval does not include 1, if RR \> 1, it favors the column defining treatment. In contrast, if RR \< 1, it favors the row defining treatment. The upper triangle is symmetrical to the lower triangle. The efficacy estimate is the ratio of the row defining treatment to the column defining treatment. The results are mutually reciprocal. Statistically significant results have been applied with italic formatting.](JIR2019-2546161.005){#fig5}

![Relative risk with 95% CIs of all interventions from network meta-analysis for sPGA 0/1 or IGA 0/1 or PGA 0/1 responses. Different interventions in the middle block divide the graph into upper and lower triangles; for the lower triangle, the efficacy estimate is the ratio of the column defining treatment to the row defining treatment. In case that the confidence interval does not include 1, if RR \> 1, it favors the column defining treatment. In contrast, if RR \< 1, it favors the row defining treatment. The upper triangle is symmetrical to the lower triangle. The efficacy estimate is the ratio of the row defining treatment to the column defining treatment. The results are mutually reciprocal. Statistically significant results have been applied with italic formatting.](JIR2019-2546161.006){#fig6}

![Relative risk with 95% CIs of all interventions from network meta-analysis for adverse events(AEs). Different interventions in the middle block divide the graph into upper and lower triangles; for the lower triangle, the efficacy estimate is the ratio of the column defining treatment to the row defining treatment. In case that the confidence interval does not include 1, if RR \> 1, it favors the row defining treatment. In contrast, if RR \< 1, it favors the column defining treatment. The upper triangle is symmetrical to the lower triangle. The efficacy estimate is the ratio of the row defining treatment to the column defining treatment. The results are mutually reciprocal. Statistically significant results have been applied with italic formatting.](JIR2019-2546161.007){#fig7}

![Relative risk with 95% CIs of all interventions from network meta-analysis for serious adverse events (sAEs). Different interventions in the middle block divide the graph into upper and lower triangles; for the lower triangle, the efficacy estimate is the ratio of the column defining treatment to the row defining treatment. In case that the confidence interval does not include 1, if RR \> 1, it favors the row defining treatment. In contrast, if RR \< 1, it favors the column defining treatment. The upper triangle is symmetrical to the lower triangle. The efficacy estimate is the ratio of the row defining treatment to the column defining treatment. The results are mutually reciprocal. Statistically significant results have been applied with italic formatting.](JIR2019-2546161.008){#fig8}

![Relative risk with 95% CIs of all interventions from network meta-analysis for Discontinuations due to AEs. Different interventions in the middle block divide the graph into upper and lower triangles; for the lower triangle, the efficacy estimate is the ratio of the column defining treatment to the row defining treatment. In case that the confidence interval does not include 1, if RR \> 1, it favors the row defining treatment. In contrast, if RR \< 1, it favors the column defining treatment. The upper triangle is symmetrical to the lower triangle. The efficacy estimate is the ratio of the row defining treatment to the column defining treatment. The results are mutually reciprocal. Statistically significant results have been applied with italic formatting.](JIR2019-2546161.009){#fig9}

![Surface under the cumulative ranking curves (SUCRA) for all interventions of all outcomes in the network meta-analysis. PASI 75: the percentages of patients with a 75% improvement from baseline in the PASI score; PASI 100: the percentages of patients with a 100% improvement from baseline in the PASI score; sPGA 0/1: static physician\'s global assessment score of 0 or 1; IGA 0/1: a response of 0 or 1 on the modified investigator\'s global assessment; PGA 0/1: physician\'s global assessment score of 0 or 1; AEs: adverse events; sAEs: serious adverse events. Alphabetic reference: A, brodalumab 140 mg; B, brodalumab 210 mg, C, guselkumab 100 mg; D, guselkumab 50 mg; E, ixekizumab 80 mg Q2W; F, ixekizumab 80 mg Q4W; G, placebo; H, risankizumab 150 mg; I, secukinumab 150 mg; J, secukinumab 300 mg; K, tildrakizumab 100 mg; L, tildrakizumab 200 mg; M, ustekinumab 45 mg; and N, ustekinumab 90 mg.](JIR2019-2546161.010){#fig10}

![Inconsistency in closed loops for all the outcomes. The graph shows the estimates of differences between direct and indirect comparisons as represented by the relative odds ratio (ROR) with 95% CIs. PASI 75: the percentages of patients with a 75% improvement from baseline in the PASI score; PASI 100: the percentages of patients with a 100% improvement from baseline in the PASI score; sPGA 0/1: static physician\'s global assessment score of 0 or 1; IGA 0/1: a response of 0 or 1 on the modified investigator\'s global assessment; PGA 0/1: physician\'s global assessment score of 0 or 1; AEs: adverse events; sAEs: serious adverse events. Alphabetic reference: A, brodalumab 140 mg; B, brodalumab 210 mg; C, guselkumab 100 mg; D, guselkumab 50 mg; E, ixekizumab 80 mg Q2W; F, ixekizumab 80 mg Q4W; G, placebo; H, risankizumab 150 mg; I, secukinumab 150 mg; J, secukinumab 300 mg; K, tildrakizumab 100 mg; L, tildrakizumab 200 mg; M, ustekinumab 45 mg; and N, ustekinumab 90 mg.](JIR2019-2546161.011){#fig11}

![Comparison-adjusted funnel plots of all the outcomes in network meta-analysis. PASI 75: the percentages of patients with a 75% improvement from baseline in the PASI score; PASI 100: the percentages of patients with a 100% improvement from baseline in the PASI score; sPGA 0/1: static physician\'s global assessment score of 0 or 1; IGA 0/1: a response of 0 or 1 on the modified investigator\'s global assessment; PGA 0/1: physician\'s global assessment score of 0 or 1; AEs: adverse events; sAEs: serious adverse events. Alphabetic reference: A, brodalumab 140 mg; B, brodalumab 210 mg; C, guselkumab 100 mg; D, guselkumab 50 mg; E, ixekizumab 80 mg Q2W; F, ixekizumab 80 mg Q4W; G, placebo; H, risankizumab 150 mg; I, secukinumab 150 mg; J, secukinumab 300 mg; K, tildrakizumab 100 mg; L, tildrakizumab 200 mg; M, ustekinumab 45 mg; and N, ustekinumab 90 mg.](JIR2019-2546161.012){#fig12}

###### 

Characteristics of the included studies.

  Author                  Year          Journal      Drug            Time to evaluate   Primary endpoint   Group         Total         Male, *N* (%)   Age (mean age)   Duration of psoriasis (years)   Involved body surface area (%)   Baseline PASI score
  ----------------------- ------------- ------------ --------------- ------------------ ------------------ ------------- ------------- --------------- ---------------- ------------------------------- -------------------------------- ---------------------
  Papp (AMAGINE-1)        2016          BJD          Brodalumab      12                 PASI 75            210 mg        222           161 (73)        46 ± 12          20 ± 13                         25.1 ± 15.3                      19.4 ± 6.6
  sPGA 0/1                140 mg        219          162 (74)        46 ± 13            19 ± 13            27.4 ± 17.1   20.0 ± 7.4                                                                                                      
  Placebo                 220           161 (73)     47 ± 13         21 ± 12            26.9 ± 17.1        19.7 ± 7.7                                                                                                                    
                                                                                                                                                                                                                                         
  Lebwohl (AMAGINE-2)     2015          NEJM         Brodalumab      12                 PASI 75            210 mg        612           421 (69)        45 ± 13          19 ± 12                         26 ± 16                          20.3 ± 8.3
  sPGA 0/1                140 mg        610          413 (68)        45 ± 13            19 ± 12            27 ± 17       20.5 ± 8.2                                                                                                      
  PASI 100                Ustekinumab   300          205 (68)        45 ± 13            19 ± 13            27 ± 19       20.0 ± 8.4                                                                                                      
  Placebo                 309           219 (71)     44 ± 13         18 ± 12            28 ± 17            20.4 ± 8.2                                                                                                                    
                                                                                                                                                                                                                                         
  Lebwohl (AMAGINE-3)     2015          NEJM         Brodalumab      12                 PASI 75            210 mg        624           431 (69)        45 ± 13          18 ± 12                         28 ± 18                          20.4 ± 8.3
  sPGA 0/1                140 mg        629          437 (70)        45 ± 13            18 ± 12            29 ± 18       20.1 ± 8.5                                                                                                      
  PASI 100                Ustekinumab   313          212 (68)        45 ± 13            17 ± 12            28 ± 18       20.1 ± 8.4                                                                                                      
  Placebo                 315           208 (66)     44 ± 13         18 ± 12            28 ± 17            20.1 ± 8.7                                                                                                                    
                                                                                                                                                                                                                                         
  Papp                    2012          NEJM         Brodalumab      12                 PASI 75            210 mg        39            28 (72)         44.0 ± 11.7      19.2 ± 9.7                      24.9 ± 16.9                      19.4 ± 8.0
  PASI 100                140 mg        39           22 (56)         42.1 ± 11.1        20.7 ± 11.8        24.1 ± 12.8   18.8 ± 5.7                                                                                                      
  Placebo                 42            30 (71)      42.3 ± 12.2     19.3 ± 12.4        21.3 ± 11.0        17.9 ± 5.5                                                                                                                    
                                                                                                                                                                                                                                         
  Nakagawa                2015          JDS          Brodalumab      12                 PASI 75            210 mg        37            29 (78.4)       46.4 ± 11.8      15.0 ± 11.0                     43.7 ± 26.0                      28.0 ± 14
  PASI 100                140 mg        37           30 (81.1)       46.4 ± 13.2        14.5 ± 9.5         42.7 ± 21.2   28.5 ± 11                                                                                                       
  sPGA 0/1                Placebo       38           27 (71.1)       46.6 ± 10.8        17.0 ± 11.4        38.0 ± 21.5   24.0 ± 9                                                                                                        
                                                                                                                                                                                                                                         
  Rich                    2012          BJD          Secukinumab     12                 PASI 75            150 mg        133           105 (78.9)      44.5 ± 12.5      17.4 ± 11.8                     22.8 ± 14.7                      19.9 ± 7.8
  Placebo                 67            44 (65.7)    44.2 ± 13.0     15.4 ± 10.7        21.7 ± 16.0        20.5 ± 9.3                                                                                                                    
                                                                                                                                                                                                                                         
  Paul (JUNCTURE)         2015          JEADV        Secukinumab     12                 PASI 75            300 mg        60            46 (76.7)       46.6 ± 14.2      21.0 ± 13.5                     26.4 ± 12.8                      18.9 ± 6.4
  IGA 0/1                 150 mg        61           41 (67.2)       43.9 ± 14.4        20.6 ± 14.5        30.1 ± 16.7   22.0 ± 8.9                                                                                                      
  Placebo                 61            38 (62.3)    43.7 ± 12.7     19.9 ± 12.2        25.7 ± 14.7        19.4 ± 6.7                                                                                                                    
                                                                                                                                                                                                                                         
  Langley (ERASURE)       2014          NEJM         Secukinumab     12                 PASI 75            300 mg        245           169 (69.0)      44.9 ± 13.5      17.4 ± 11.1                     32.8 ± 19.3                      22.5 ± 9.2
  IGA 0/1                 150 mg        245          168 (68.6)      44.9 ± 13.3        17.5 ± 12.0        33.3 ± 19.2   22.3 ± 9.8                                                                                                      
  Placebo                 248           172 (69.4)   45.4 ± 12.6     17.3 ± 12.4        29.7 ± 15.9        21.4 ± 9.1                                                                                                                    
                                                                                                                                                                                                                                         
  Langley (FIXTURE)       2014          NEJM         Secukinumab     12                 PASI 75            300 mg        327           224 (68.5)      44.5 ± 13.2      15.8 ± 12.3                     34.3 ± 19.2                      23.9 ± 9.9
  IGA 0/1                 150 mg        327          236 (72.2)      45.4 ± 12.9        17.3 ± 12.2        34.5 ± 19.4   23.7 ± 10.5                                                                                                     
  Placebo                 326           237 (72.7)   44.1 ± 12.6     16.6 ± 11.6        35.2 ± 19.1        24.1 ± 10.5                                                                                                                   
                                                                                                                                                                                                                                         
  Blauvelt (FEATURE)      2015          BJD          Secukinumab     12                 PASI 75            300 mg        59            38 (64.4)       45.1 ± 12.6      18.0 ± 11.9                     33.3 ± 18.0                      20.7 ± 8.0
  IGA 0/1                 150 mg        59           40 (67.8)       46.0 ± 15.1        20.4 ± 13.0        30.6 ± 16.6   20.5 ± 8.3                                                                                                      
  Placebo                 59            39 (66.1)    46.5 ± 14.1     20.2 ± 14.2        32.2 ± 17.4        21.1 ± 8.5                                                                                                                    
                                                                                                                                                                                                                                         
  Gordon (UNCOVER-1)      2016          NEJM         Ixekizumab      12                 PASI 75            80 mg Q4W     432           289 (66.9)      46 ± 13          19 ± 12                         27 ± 16                          20 ± 8
  sPGA 0/1                80 mg Q2W     433          291 (67.2)      45 ± 12            20 ± 12            28 ± 18       20 ± 7                                                                                                          
  Placebo                 431           303 (70.3)   46 ± 13         20 ± 12            27 ± 18            20 ± 9                                                                                                                        
                                                                                                                                                                                                                                         
  Griffiths (UNCOVER-2)   2015          Lancet       Ixekizumab      12                 PASI 75            80 mg Q4W     347           244 (70.3)      45 ± 14          19 ± 13                         27 ± 17                          20 ± 7
  sPGA 0/1                80 mg Q2W     351          221 (63.0)      45 ± 13            18 ± 12            25 ± 16       19 ± 7                                                                                                          
  Placebo                 168           120 (71.4)   45 ± 12         19 ± 13            27 ± 18            21 ± 8                                                                                                                        
                                                                                                                                                                                                                                         
  Griffiths (UNCOVER-3)   2015          Lancet       Ixekizumab      12                 PASI 75            80 mg Q4W     386           258 (66.8)      46 ± 13          18 ± 12                         28 ± 16                          21 ± 8
  sPGA 0/1                80 mg Q2W     385          254 (66.0)      46 ± 13            18 ± 12            28 ± 17       21 ± 8                                                                                                          
  Placebo                 193           137 (71.0)   46 ± 12         18 ± 13            29 ± 17            21 ± 8                                                                                                                        
                                                                                                                                                                                                                                         
  IGARASHI                2012          JD           Ustekinumab     12                 PASI 75            45 mg         64            53 (82.8)       45               15.8 ± 8.2                      47 ± 23.7                        30 ± 12.9
  90 mg                   62            47 (75.8)    44              17.3 ± 10.7        47 ± 19.7          29 ± 11.2                                                                                                                     
  Placebo                 32            26 (83.9)    49              16.0 ± 11.2        50 ± 22.5          30 ± 11.8                                                                                                                     
                                                                                                                                                                                                                                         
  Leonardi (PHOENIX 1)    2008          Lancet       Ustekinumab     12                 PASI 75            45 mg         255           175 (68·6)      44.8             19.7                            27.2                             20.5
  90 mg                   256           173 (67·6)   46.2            19.6               25.2               19.7                                                                                                                          
  Placebo                 255           183 (71·8)   44.8            20.4               27.7               20.4                                                                                                                          
                                                                                                                                                                                                                                         
  Papp (PHOENIX 2)        2008          Lancet       Ustekinumab     12                 PASI 75            45 mg         409           283 (69·2)      45.1             19.3                            25.9                             19.4
  90 mg                   411           274 (66·7)   46.6            20.3               27.1               20.1                                                                                                                          
  Placebo                 410           283 (69·0)   47.0            20.8               26.1               19.4                                                                                                                          
                                                                                                                                                                                                                                         
  Tsai (PEARL)            2011          JDS          Ustekinumab     12                 PASI 75            45 mg         61            50 (82.0)       40.9 ± 12.7      11.9 ± 7.5                      41.8 ± 24.4                      25.2 ± 11.9
  Placebo                 60            53 (88.3)    40.4 ± 10.1     13.9 ± 7.3         35.8 ± 21.4        22.9 ± 8.6                                                                                                                    
                                                                                                                                                                                                                                         
  Zhu (LOTUS)             2013          JDD          Ustekinumab     12                 PASI 75            45 mg         160           125 (78.1)      40.1 ± 12.4      14.6 ± 8.9                      35.1 ± 18.5                      23.2 ± 9.5
  Placebo                 162           123 (75.9)   39.2 ± 12.2     14.2 ± 8.6         35.1 ± 19.6        22.7 ± 9.5                                                                                                                    
                                                                                                                                                                                                                                         
  Krueger                 2007          NEJM         Ustekinumab     12                 PASI 75            45 mg         64            39 (61)         45 ± 12          19.8 ± 11.9                     27.4 ± 16.9                      18.9 ± 7.0
  90 mg                   64            52 (81)      44 ± 13         17.3 ± 13.5        27.4 ± 18.1        19.0 ± 7.9                                                                                                                    
  Placebo                 64            46 (72)      44 ± 14         16.9 ± 11.0        26.6 ± 18.4        19.9 ± 8.3                                                                                                                    
                                                                                                                                                                                                                                         
  Blauvelt (VOYAGE 1)     2017          JAAD         Guselkumab      16                 IGA 0/1            100 mg        329           240 (72.9)      43.9 ± 12.7      17.9 ± 12.3                     28.3 ± 17.1                      22.1 ± 9.5
  PASI 90                 Placebo       174          119 (68.4)      44.9 ± 12.9        17.6 ± 12.4        25.8 ± 15.9   20.4 ± 8.7                                                                                                      
                                                                                                                                                                                                                                         
  Reich (VOYAGE 2)        2017          JAAD         Guselkumab      16                 IGA 0/1            100 mg        496           349 (70.4)      43.7 ± 12.2      17.9 ± 12.0                     28.5 ± 16.4                      21.9 ± 8.8
  PASI 90                 Placebo       248          173 (69.8)      43.3 ± 12.4        17.9 ± 11.9        28.0 ± 16.5   21.5 ± 8.0                                                                                                      
                                                                                                                                                                                                                                         
  Gordon                  2015          NEJM         Guselkumab      16                 PGA 0/1            50 mg         42            28 (67)         43               19                              25                               19
  100 mg                  42            31 (74)      42              18                 24                 21                                                                                                                            
  Placebo                 42            28 (67)      46.5            18                 28                 22                                                                                                                            
                                                                                                                                                                                                                                         
  OHTSUKI                 2017          JD           Guselkumab      16                 IGA 0/1            50 mg         65            44 (67.7)       50.1             15.25                           38.0                             25.60
  PASI 90                 100 mg        63           47 (74.6)       47.8               14.39              37.9          26.73                                                                                                           
  Placebo                 64            54 (84.4)    48.3            13.66              33.6               25.92                                                                                                                         
                                                                                                                                                                                                                                         
  Papp                    2015          BJD          Tildrakizumab   16                 PASI 75            100 mg        89            76 (85)         45.5 ± 12.8      NR                              NR                               NR
  200 mg                  86            65 (76)      43.2 ± 12.6     NR                 NR                 NR                                                                                                                            
  Placebo                 46            38 (83)      45.9 ± 11.7     NR                 NR                 NR                                                                                                                            
                                                                                                                                                                                                                                         
  Reich (reSURFACE 1)     2017          Lancet       Tildrakizumab   12                 PASI 75            100 mg        309           207 (67)        46.4             NR                              29.7                             20.0
  PGA 0/1                 200 mg        308          226 (73)        46.9               NR                 30.9          20.7                                                                                                            
  Placebo                 155           100 (65)     47.9            NR                 29.6               19.3                                                                                                                          
                                                                                                                                                                                                                                         
  Reich (reSURFACE 2)     2017          Lancet       Tildrakizumab   12                 PASI 75            100 mg        307           220 (72)        44.6             NR                              34.2                             20.5
  PGA 0/1                 200 mg        314          225 (72)        44.6               NR                 31.8          19.8                                                                                                            
  Placebo                 313           222 (71)     45.8            NR                 31.6               20.2                                                                                                                          
                                                                                                                                                                                                                                         
  Gordon (UltIMMa-1)      2018          Lancet       Risankizumab    16                 PASI 90            150 mg        304           212 (70)        48.3             NR                              26.2                             20.6
  sPGA 0/1                Ustekinumab   100          70 (70)         46.5               NR                 25.2          20.1                                                                                                            
  Placebo                 102           79 (77)      49.3            NR                 27.9               20.5                                                                                                                          
                                                                                                                                                                                                                                         
  Gordon (UltIMMa-1)      2018          Lancet       Risankizumab    16                 PASI 90            150 mg        294           203 (69)        46.2             NR                              26.2                             20.5
  sPGA 0/1                Ustekinumab   99           66 (67)         48.6               NR                 20.9          18.2                                                                                                            
  Placebo                 98            67 (68)      46.3            NR                 23.9               18.9                                                                                                                          

Data are presented as the numbers (%) or the means ± standard deviations. PASI 75: the percentages of patients with a 75% improvement from baseline in the PASI score; PASI 90: the percentages of patients with a 90% improvement from baseline in the PASI score; PASI 100: the percentages of patients with a 100% improvement from baseline in the PASI score; sPGA 0/1: static physician\'s global assessment score of 0 or 1; IGA 0/1: a response of 0 or 1 on the modified investigator\'s global assessment; PGA 0/1: physician\'s global assessment score of 0 or 1; Q2W: every 2 weeks; Q4W: every 4 weeks; NR: not reported.

###### 

Summary of pooled major clinical responses and adverse events during short-time treatment.

  Author                  Drug            Time to evaluate   Group       Total   PASI 75   PASI 100   sPGA 0/1   IGA 0/1   PGA 0/1   AEs   sAEs   Discontinuations due to AEs
  ----------------------- --------------- ------------------ ----------- ------- --------- ---------- ---------- --------- --------- ----- ------ -----------------------------
  Papp (AMAGINE-1)        Brodalumab      12                 210 mg      222     185       93         168        NR        NR        131   4      2
  140 mg                  219             132                51          118     NR        NR         126        6         3                      
  Placebo                 220             6                  1           3       NR        NR         112        3         3                      
                                                                                                                                                  
  Lebwohl (AMAGINE-2)     Brodalumab      12                 210 mg      612     528       272        481        NR        NR        354   6      3
  140 mg                  610             406                157         354     NR        NR         365        13        4                      
  Ustekinumab             300             210                65          183     NR        NR         177        4         2                      
  Placebo                 309             25                 2           12      NR        NR         165        8         0                      
                                                                                                                                                  
  Lebwohl (AMAGINE-3)     Brodalumab      12                 210 mg      624     531       229        497        NR        NR        353   9      4
  140 mg                  629             435                170         377     NR        NR         329        10        4                      
  Ustekinumab             313             217                19          179     NR        NR         168        2         1                      
  Placebo                 315             19                 1           13      NR        NR         152        3         0                      
                                                                                                                                                  
  Papp                    Brodalumab      12                 210 mg      40      33        25         32         NR        NR        33    1      0
  140 mg                  39              30                 15          33      NR        NR         27         0         0                      
  Placebo                 38              0                  0           1       NR        NR         23         1         0                      
                                                                                                                                                  
  Nakagawa                Brodalumab      12                 210 mg      37      35        22         35         NR        NR        27    1      0
  140 mg                  37              29                 13          29      NR        NR         21         0         0                      
  Placebo                 38              3                  0           2       NR        NR         17         1         1                      
                                                                                                                                                  
  Rich                    Secukinumab     12                 150 mg      133     72        NR         NR         49        NR        89    6      3
  Placebo                 67              1                  NR          NR      1         NR         47         1         1                      
                                                                                                                                                  
  Paul (JUNCTURE)         Secukinumab     12                 300 mg      60      52        16         NR         44        NR        42    1      0
  150 mg                  61              44                 10          NR      33        NR         39         3         0                      
  Placebo                 61              2                  0           NR      0         NR         33         1         1                      
                                                                                                                                                  
  Langley (ERASURE)       Secukinumab     12                 300 mg      245     200       70         NR         160       NR        135   4      5
  150 mg                  245             174                31          NR      125       NR         148        4         4                      
  Placebo                 248             11                 2           NR      6         NR         116        4         4                      
                                                                                                                                                  
  Langley (FIXTURE)       Secukinumab     12                 300 mg      327     249       78         NR         202       NR        181   4      4
  150 mg                  327             219                47          NR      167       NR         191        7         2                      
  Placebo                 326             16                 0           NR      9         NR         163        6         3                      
                                                                                                                                                  
  Blauvelt (FEATURE)      Secukinumab     12                 300 mg      59      46        25         NR         41        NR        30    3      1
  150 mg                  59              41                 5           NR      31        NR         34         0         0                      
  Placebo                 59              0                  0           NR      0         NR         28         1         1                      
                                                                                                                                                  
  Gordon (UNCOVER-1)      Ixekizumab      12                 80 mg Q4W   432     357       145        330        NR        NR        264   12     10
  80 mg Q2W               433             386                153         354     NR        NR         257        6         10                     
  Placebo                 431             17                 2           14      NR        NR         210        5         6                      
                                                                                                                                                  
  Griffiths (UNCOVER-2)   Ixekizumab      12                 80 mg Q4W   347     269       107        253        NR        NR        204   8      5
  80 mg Q2W               351             315                142         292     NR        NR         216        5         4                      
  Placebo                 168             4                  1           4       NR        NR         89         2         1                      
                                                                                                                                                  
  Griffiths (UNCOVER-3)   Ixekizumab      12                 80 mg Q4W   386     325       135        291        NR        NR        215   6      9
  80 mg Q2W               385             336                145         310     NR        NR         205        9         8                      
  Placebo                 193             14                 0           13      NR        NR         70         5         2                      
                                                                                                                                                  
  IGARASHI                Ustekinumab     12                 45 mg       64      38        NR         NR         NR        37        42    0      0
  90 mg                   62              42                 NR          NR      NR        43         37         3         4                      
  Placebo                 32              2                  NR          NR      NR        3          21         2         2                      
                                                                                                                                                  
  Leonardi (PHOENIX 1)    Ustekinumab     12                 45 mg       255     171       32         NR         NR        154       147   2      1
  90 mg                   256             170                28          NR      NR        158        131        4         4                      
  Placebo                 255             8                  0           NR      NR        10         123        2         6                      
                                                                                                                                                  
  Papp (PHOENIX 2)        Ustekinumab     12                 45 mg       409     273       74         NR         NR        278       217   8      1
  90 mg                   411             311                75          NR      NR        302        197        5         6                      
  Placebo                 410             15                 0           NR      NR        20         204        8         8                      
                                                                                                                                                  
  Tsai (PEARL)            Ustekinumab     12                 45 mg       61      41        5          NR         NR        43        40    0      0
  Placebo                 60              3                  0           NR      NR        5          42         2         3                      
                                                                                                                                                  
  Zhu(LOTUS)              Ustekinumab     12                 45 mg       160     132       38         NR         NR        126       68    1      3
  Placebo                 162             18                 1           NR      NR        24         62         1         2                      
                                                                                                                                                  
  Krueger                 Ustekinumab     12                 45 mg       64      43        10         NR         NR        46        49    2      1
  90 mg                   64              52                 13          NR      NR        53         42         3         1                      
  Placebo                 64              1                  0           NR      NR        0          48         1         2                      
                                                                                                                                                  
  Blauvelt (VOYAGE 1)     Guselkumab      16                 100 mg      329     300       123        NR         280       NR        170   8      4
  Placebo                 174             10                 1           NR      12        NR         86         3         2                      
                                                                                                                                                  
  Reich (VOYAGE 2)        Guselkumab      16                 100 mg      496     328       169        NR         417       NR        235   8      7
  Placebo                 248             20                 2           NR      21        NR         111        3         2                      
                                                                                                                                                  
  Gordon                  Guselkumab      16                 50 mg       42      34        8          NR         NR        33        21    3      NA
  100 mg                  42              33                 14          NR      NR        36         19         0         5                      
  Placebo                 42              2                  0           NR      NR        3          22         1         3                      
                                                                                                                                                  
  OHTSUKI                 Guselkumab      16                 50 mg       65      58        21         NR         60        NR        30    1      1
  100 mg                  63              53                 17          NR      56        NR         29         1         0                      
  Placebo                 64              4                  0           NR      5         NR         36         2         6                      
                                                                                                                                                  
  Papp                    Tildrakizumab   12                 100 mg      89      54        NA         NR         NR        55        58    1      1
  200 mg                  86              62                 NA          NR      NR        64         54         2         1                      
  Placebo                 46              2                  NA          NR      NR        1          31         0         1                      
                                                                                                                                                  
  Reich (reSURFACE 1)     Tildrakizumab   12                 100 mg      309     197       43         NR         NR        179       146   5      0
  200 mg                  308             192                43          NR      NR        182        130        8         5                      
  Placebo                 155             9                  2           NR      NR        11         74         1         1                      
                                                                                                                                                  
  Reich (reSURFACE 2)     Tildrakizumab   12                 100 mg      307     188       38         NR         NR        168       136   4      3
  200 mg                  314             206                37          NR      NR        186        155        6         3                      
  Placebo                 156             9                  0           NR      NR        7          86         4         2                      
                                                                                                                                                  
  Gordon (UltIMMa-1)      Risankizumab    16                 150 mg      304     264       109        267        NR        NR        151   7      2
  Ustekinumab             100             70                 12          63      NR        NR         50         8         2                      
  Placebo                 102             10                 0           8       NR        NR         52         3         4                      
                                                                                                                                                  
  Gordon (UltIMMa-2)      Risankizumab    16                 150 mg      294     261       149        246        NR        NR        134   6      1
  Ustekinumab             99              69                 24          62      NR        NR         53         3         0                      
  Placebo                 98              8                  2           5       NR        NR         45         1         1                      

PASI 75: the percentages of patients with a 75% improvement from baseline in the PASI score; PASI 100: the percentages of patients with a 100% improvement from baseline in the PASI score; sPGA 0/1: static physician\'s global assessment score of 0 or 1; IGA 0/1: a response of 0 or 1 on the modified investigator\'s global assessment; PGA 0/1: physician\'s global assessment score of 0 or 1; AEs: adverse events; sAEs: serious adverse events; Q2W: every 2 weeks; Q4W: every 4 weeks; NR: not reported; NA: not available.

###### 

Ranking for all the outcomes of the interventions included at 12 or 16 weeks in the network meta-analysis.

  Interventions          PASI 75   PASI 100   sPGA 0/1 or IGA 0/1 or PGA 0/1   AEs    sAEs   Discontinuations due to AEs                                                                                
  ---------------------- --------- ---------- -------------------------------- ------ ------ ----------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  Brodalumab 140 mg      22.8      0.0        11.0                             63.4   0.5    5.8                           32.0   0.0    9.8    38.1   0.0    9.0    38.4   0.1    9.0    54.2   0.6    7.0
  Brodalumab 210 mg      62.5      0.3        5.9                              85.0   28.4   2.9                           65.4   0.1    5.5    23.7   0.0    10.9   63.9   3.8    5.7    63.0   0.9    5.8
  Guselkumab 100 mg      28.5      0.0        10.3                             61.4   6.0    6.0                           31.4   0.0    9.9    63.4   1.3    5.8    49.4   3.3    7.6    32.1   0.2    9.8
  Guselkumab 50 mg       38.7      0.4        9.0                              55.9   4.3    6.7                           33.4   0.0    9.7    76.2   30.1   4.1    25.9   3.5    10.6   84.6   36.7   3.0
  Ixekizumab 80 mg Q2W   93.0      53.4       1.9                              83.3   32.7   3.2                           86.5   13.3   2.8    7.5    0.0    13.0   50.8   3.1    7.4    14.8   0.0    12.1
  Ixekizumab 80 mg Q4W   81.5      0.5        3.4                              76.8   12.9   4.0                           75.7   0.0    4.2    4.5    0.0    13.4   27.5   0.5    10.4   10.7   0.0    12.6
  Placebo                0.0       0.0        14.0                             0.0    0.0    14.0                          0.0    0.0    14.0   67.3   0.0    5.3    59.4   0.1    6.3    39.7   0.0    8.8
  Risankizumab 150 mg    62.3      0.4        5.9                              71.3   6.4    4.7                           66.7   0.4    5.3    67.6   5.3    5.2    92.8   61.5   1.9    92.6   53.2   2.0
  Secukinumab 150 mg     73.5      0.0        4.4                              31     0.1    10.0                          85.7   0.0    2.9    22.7   0.0    11.0   30.7   0.4    10.0   43.5   0.2    8.4
  Secukinumab 300 mg     89.9      43.1       2.3                              62.4   8.3    5.9                           98.1   86.0   1.3    33.9   0.0    9.6    35.6   0.9    9.4    42.2   0.1    8.5
  Tildrakizumab 100 mg   33.2      0.2        9.7                              21.9   0.4    11.2                          22.3   0.0    11.1   88.8   27.9   2.5    70.8   18.9   4.8    58.6   4.5    6.4
  Tildrakizumab 200 mg   42.2      1.7        8.5                              20.0   0.0    11.4                          34.7   0.2    9.5    90.2   31.3   2.3    41.1   1.2    8.7    35.4   0.4    9.4
  Ustekinumab 45 mg      27.4      0.0        10.4                             33.1   0.0    9.7                           25.4   0.0    10.7   41.0   0.0    8.7    61.1   0.6    6.1    79.0   3.0    3.7
  Ustekinumab 90 mg      44.5      0.0        8.2                              34.5   0.0    9.5                           42.8   0.0    8.4    75.2   4.1    4.2    52.5   2.1    7.2    49.7   0.2    7.5

SUCRA: surface under the cumulative ranking; PrBest: probability of best treatment; PrHighest risk: probability of the highest risk of AEs; PASI 75: the percentages of patients with a 75% improvement from baseline in the PASI score; PASI 100: the percentages of patients with a 100% improvement from baseline in the PASI score; sPGA 0/1: static physician\'s global assessment score 0 or 1; IGA 0/1: a response of 0 or 1 on the modified investigator\'s global assessment; PGA 0/1: physician\'s global assessment score of 0 or 1; AEs: adverse events; sAEs: serious adverse events; Q2W: every 2 weeks; Q4W: every 4 weeks.
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